- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Health Plan Could Save $1B Per Year with Generic Drugs
Excellus BlueCross BlueShield says it could save $460 million to $1 billion per year if its customers use more generic drugs instead of name-brand prescriptions, according to a new report from the insurer.
That's because the average 30-day costs for brand drugs have risen exponentially--a 73% increase from $120 to $208 over the last 5 years--compared to generics, which actually decreased 7.5% from $19 to $18, the Rochester Democrat and Chronicle reports.
Read more at: http://tinyurl.com/6uav2ts
Source: Fierce Health Payer
Adding to this cost trend is the fact that "no less than 42 brand-name drugs either have or will become available as generics in 2011 and 2012, which easily can mean a 2-point to 4-point increase in the upstate New York generic fill rate," says Joel Owerbach, Excellus vice president and chief pharmacy officer.
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
